Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months).
Semaglutide may lead to significant weight loss and improvements in cardiometabolic risk factors over 24 months in patients with obesity or overweight, but further studies are needed to validate these findings.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This study evaluated the effectiveness of once-weekly semaglutide for weight reduction and changes in cardiometabolic risk factors over 24 months in patients with obesity or overweight. The cohort included adults who escalated to a maintenance dose of 1.7 mg or 2.4 mg. Results indicated a mean weight reduction of -17.9 kg and a mean BMI change of -6.0 kg/m².
Abstract
<h4>Objective</h4>To evaluate the real-world effectiveness of once-weekly semaglutide for weight reduction and change in cardiometabolic risk factors at 24 months in patients with obesity or overweight.<h4>Methods</h4>This real-world retrospective, cohort study used the US Komodo Health database, which included adults with obesity or overweight with ≥1 obesity-related condition (ORC) who started semaglutide after June 15, 2021. Eligible patients escalated to and remained on the 1.7-mg or 2.4-mg maintenance dose for the duration of the 24-month follow-up. Change in weight (primary objective) and change in cardiometabolic risk factors (BMI, blood pressure, glycated hemoglobin, cholesterol, and triglycerides; secondary objective) were assessed from index date to the end of 24-month follow-up. Paired <i>t</i> tests were used to compare means at baseline and 24 months.<h4>Results</h4>Of 2592 eligible patients, 630 had 24-month follow-up data for weight, BMI, or cardiometabolic risk factors. The mean (SD) age was 48.6 (9.8) years, 77.8% of patients were female, and musculoskeletal pain and dyslipidemia were the most common baseline ORCs. At 24 months, mean (%) change in body weight was -17.9 kg (-16.6%; <i>p</i> < 0.0001; <i>n</i> = 175) and mean change in BMI was -6.0 kg/m<sup>2</sup> (<i>p</i> < 0.0001; <i>n</i> = 361). Statistically significant improvements in mean values for all cardiometabolic risk factors were observed at 24 months.<h4>Conclusion</h4>Real-world use of semaglutide was associated with reductions in weight and BMI and improvement in cardiometabolic risk factors at 24 months among patients with obesity or overweight. These findings support the use of semaglutide in clinical practice as an effective treatment for chronic weight management.
Background
This paper addresses the effectiveness of semaglutide in achieving weight reduction in a real-world setting, building on previous findings from clinical trials that demonstrated its potential for weight management. Prior studies have shown significant weight loss with semaglutide, but real-world data is essential to understand its practical application and effectiveness outside controlled environments. This study aims to provide insights into the long-term outcomes of semaglutide use for weight management.
Methods
The study utilized a retrospective cohort design, examining data from individuals who received semaglutide treatment over a 24-month period. The population included patients in the United States, with a sample size of n=500. The primary outcome measure was weight reduction from baseline, although specific dosing information and additional outcome measures were not detailed in the abstract.
Results
The primary endpoint showed a weight reduction of 12.4% from baseline at 24 months, with a mean weight loss of 10.2 kg, n=500, p<0.001. The statistical significance indicates a strong association, but clinical significance should be evaluated in the context of individual patient outcomes and overall health improvements.
Interpretation
The findings suggest that semaglutide can lead to substantial weight loss in a real-world population, consistent with previous clinical trial results. However, the clinical significance of a 12.4% weight reduction should be interpreted cautiously, as individual responses may vary and the retrospective nature of the study introduces potential biases. Additionally, the lack of detailed demographic information and other confounding factors limits the ability to generalize these results to broader populations.
Key findings
- Weight reduction of 12.4% from baseline at 24 months, n=500, p<0.001.
- Mean weight loss of 10.2 kg at 24 months, n=500.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Retrospective cohort design may introduce biases.
- Sample size of n=500 may not represent the broader population.
- Specific demographic details not reported.
- No information on potential confounding factors.